

REDEFINE

Clinical Trial

ControlRad Select significantly reduces radiation dose for everyone in the Cath Lab

Trial Design

The REDEFINE trial evaluated whether the ControlRad system reduces radiation exposure to operators and the patient during diagnostic and interventional cardiac catheterization procedures



Prospective, single center, randomized trial



Cardiac Cath ± PCI
N=80



Exclusions: STEMI, shock, peripheral procedures, pericardiocentesis


R

Cath with
CONTROLRAD

Cath without
CONTROLRAD

Results

Primary Endpoint: Radiation dose to primary operator at thyroid



Secondary Endpoint: Dose area product (DAP), radiation dose to secondary operator, radiation dose at a fixed point on the cath lab wall



Secondary Operator
49% ↓
reduction in radiation dose



Circulating Nurse*
38% ↓
reduction in radiation dose



Patient
35% ↓
reduction in radiation dose



**Boston
Scientific**
Advancing science for life™

Interventional Cardiology
300 Boston Scientific Way
Marlborough, MA 01752-1234
www.bostonscientific.com

*To order product or for more information
contact customer service at 1.888.272.1001.*

© 2022 Boston Scientific Corporation
or its affiliates. All rights reserved.

IC-1225208-AA

REDEFINE: A Prospective, Randomized Evaluation of the
ControlRad System to Reduce Radiation Exposure During
Cardiac Catheterization Procedures; Simon Dixon, MD; TCT 2021
All trademarks are property of their respective owners.